ASCO 2023 | KEYNOTE-716: pembrolizumab in stage 2B/2C cutaneous melanoma

Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, provides an overview of the Phase III KEYNOTE-716 (NCT03553836), which assessed pembrolizumab in patients with high risk stage 2B or 2C cutaneous melanoma. The previous primary endpoint of relapse-free survival was met, and the trial aims to elucidate the best course of treatment in the adjuvant setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.